Opinion|Videos|March 7, 2025

KarMMa-3 Trial: Additional Insights From Ide-Cel in RRMM

Panelists discuss how detailed analyses from KarMMa-3 reveal key insights about ide-cel’s performance across patient subgroups, timing of responses, durability of remissions, and management of adverse effects in relapsed/refractory multiple myeloma (RRMM).

Episodes in this series


Latest CME